4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc.
Your view on FDMT
Overview
What the company does, where it operates, and who runs it.
About 4D Molecular Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David H. Kirn
- Headquarters
- 5858 Horton Street, EmeryVille, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David H. Kirn
- Headquarters
- 5858 Horton Street, EmeryVille, CA, US
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for 4D Molecular Therapeutics, Inc. from FRC's valuation model, read against the market price. FDMT last traded at $12.99; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for 4D Molecular Therapeutics, Inc.. Starting points for 4D Molecular Therapeutics, Inc.: EPS -$2.55, beta 2.91 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for 4D Molecular Therapeutics, Inc.. 4D Molecular Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for 4D Molecular Therapeutics, Inc.. Trailing twelve-month EPS for 4D Molecular Therapeutics, Inc. stands at -$2.55. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$20.00
Median
$32.00
High
$37.00
Average target · 3 new targets in the last 3 months, average $29.67
Analyst Ratings
- Strong Buy0
- Buy11
- Hold2
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$1.05 | -$1.06 | -$4.15 | -$4.09 |
| Low estimate | -$1.08 | -$1.13 | -$4.31 | -$4.34 |
| High estimate | -$1.00 | -$1.02 | -$4.03 | -$3.50 |
| No. of analysts | 7 | 7 | 8 | 7 |
| Year-ago EPS | -$1.01 | $0.34 | -$2.42 | — |
| Growth | -4.0% | -412.2% | -71.5% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $4.13M | $5.17M | $13.26M | $18.34M |
| Low estimate | $3.79M | $5.11M | $7.20M | $16.25M |
| High estimate | $4.48M | $5.22M | $16.87M | $20.43M |
| No. of analysts | 5 | 5 | 8 | 6 |
| Year-ago revenue | $90000.00 | $85.09M | $85.21M | — |
| Growth | +4492.6% | -93.9% | -84.4% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for 4D Molecular Therapeutics, Inc.. 4D Molecular Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
4D Molecular Therapeutics, Inc. valued side by side against its closest peers. 4D Molecular Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold 4D Molecular Therapeutics, Inc., and how their positions are changing. At a $717.6M market value, institutional positions materially move 4D Molecular Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by 4D Molecular Therapeutics, Inc. executives and directors. Shares of 4D Molecular Therapeutics, Inc. have traded between $2.23 and $12.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for 4D Molecular Therapeutics, Inc.. Coverage tracks 4D Molecular Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of 4D Molecular Therapeutics, Inc.